News | August 02, 2021
Granules India earmarks Rs 400 crore as Capex for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Indian government is expecting pharmaceutical industry to fetch incremental sales worth Rs. 294,000 crore and exports up to Rs. 196,000 crore by FY 2027-28
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
Subscribe To Our Newsletter & Stay Updated
